- REAL-WORLD TREATMENT PATTERNS (TXP) AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER (NMCRPC) AND METASTATIC HORMONE-SENSITIVEPROSTATE CANCER (MHSPC) IN CHINAWang, Y.; Liu, C.; Liu, C.; Lu, Y.; Ban, L.; Niu, Y.; Udayachalerm, S.
- Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancerMeijun, Du; Yijun, Tian; Winston, Tan; Liewei, Wang; Liguo, Wang; Deepak, Kilari; Chiang-Ching, Huang; Liang, Wang; Manish, KohliPROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23(4): 705-713.被引 2
- A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumorsLi, Huiping; Huang, Yan; Zhang, Li; Chen, Zhendong; Zeng, Aiping; Zhang, Helong; Yu, Yan; Wei, Shihong; Li, Qingshan; Wang, Xiaojia; Wang, Xiangcai; Wang, Xiuwen; Yang, Runxiang; Dai, Xiumei; Bi, Minghong; Sun, Tao; Zhang, Qingyuan; Han, Cuicui; Liu, Qianqian; Li, YujieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
期刊论文
Treatment patterns of prostate cancer with bone metastasis in Beijing: A real坼world study using data from an administrative claims database
2被引9阅读
